NCT01795183View on ClinicalTrials.gov

Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia

PHASE4CompletedINTERVENTIONAL
Enrollment

316

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Schizophrenia
Interventions
DRUG

AMISULPRIDE

Pharmaceutical form: tablet Route of administration: oral

Trial Locations (1)

Unknown

Sanofi-Aventis Administrative Office, Beijing

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT01795183 - Effectiveness and Safety of Amisulpride in Chinese Patients With Schizophrenia | Biotech Hunter | Biotech Hunter